The 4′-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells

Investigational New Drugs

Volumn 25, Issue 2, 2007, Pages 115-122

  Brooks, Tracy A ^a,b   O'Loughlin, Kieran L ^a   Minderman, Hans ^a   Bundy, Brian N ^a   Ford, Laurie A ^a   Vredenburg, Michael R ^a   Bernacki, Ralph J ^a   Priebe, Waldemar ^c   Baer, Maria R ^a,d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Roswell Park Cancer Institude ^*  (United States)

Author keywords

Acute myeloid leukemia; Breast cancer resistance protein; Multidrug resistance protein; P glycoprotein; WP744

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; DAUNORUBICIN; DOXORUBICIN; DOXORUBICIN DERIVATIVE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; UNCLASSIFIED DRUG; WP 744; ABCG2 PROTEIN, HUMAN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG UPTAKE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE; CELL SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; FLUORESCENCE; GENETICS; METABOLISM; MIDDLE AGED; MYELOID LEUKEMIA; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADULT; AGED; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL SURVIVAL; DAUNORUBICIN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENCE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASM PROTEINS; P-GLYCOPROTEIN;

EID: 33845900964     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-9018-3     Document Type: Article

References (17)

1. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58
2. Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W (2001) WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res 21:3777-3784
3. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M, Bates SE (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635-q6639
4. Minderman H, Suvannasankha A, O'Loughlin KL, Scheffer GL, Scheper RJ, Robey RW, Baer MR (2002) Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 48:59-65
5. Brooks TA, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ (2003) Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein. Mol Cancer Ther 2:1195-1205
6. Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, Baer MR (2005) Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 11:2320-2326
7. Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Greco WR, Ross DD, Baer MR (2004) Breast cancer resistance protein in acute myeloid leukemia: discordance between expression and function. Leukemia 18:1252-1257
8. Ashikawa K, Shishodia S, Fokt I, Priebe W, Aggarwal BB (2004) Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem Pharmacol 67:353-364
9. Inge TH, Harris NL, Wu J, Azizkhan RG, Priebe W (2004) WP744 is a novel anthracycline with enhanced activity against neuroblastoma. J Surg Res 121:187-196
10. Wu J, Harris NL, Inge TH (2004) Nuclear factor-kappa B and apoptosis inducing factor activation by doxorubicin analog WP744 in SH-SY5Y neuroblastoma cells. J Surg Res 122:231-239
11. Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, Yang W, Wei D, Ross DD (2003) Quantitative analysis of breast cancer resistance protein (BCRP) and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res 9:3320-3328
12. Plasschaert SL, van der Kolk DM, de Bont ES, Kamps WA, Morisaki K, Bates SE, Scheffer GL, Scheper RJ, Vellenga E, de Vries EG (2003) The role of breast cancer resistance protein in acute lymphoblastic leukemia. Clin Cancer Res 9:5171-5177
13. Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Ford LA, Greco WR, Wetzler M, Ross DD, Baer MR (2004) Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. Brit J Haematol 127:392-398
14. Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper RJ, Taylor CG (2001) Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol 115:257-262
15. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A (2002) BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16:1443-1447
16. Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP, Legrand O (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 10:7896-7902
17. Löscher W, Potschka H (2005) Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2:86-98